Abstract
Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40% variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 185-188 |
| Number of pages | 4 |
| Journal | Expert review of vaccines |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2014 |
| Externally published | Yes |
Keywords
- T cells
- antibodies
- dengue
- live-attenuated
- vaccine
ASJC Scopus subject areas
- Immunology
- Molecular Medicine
- Pharmacology
- Drug Discovery